Cencora, Inc. (NYSE:COR) Expected to Earn Q1 2025 Earnings of $3.46 Per Share

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs boosted their Q1 2025 earnings per share (EPS) estimates for shares of Cencora in a report released on Wednesday, July 31st. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $3.46 per share for the quarter, up from their previous estimate of $3.45. The consensus estimate for Cencora’s current full-year earnings is $13.56 per share. Leerink Partnrs also issued estimates for Cencora’s Q4 2025 earnings at $3.66 EPS, FY2025 earnings at $14.96 EPS and FY2026 earnings at $16.60 EPS.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period last year, the business earned $2.92 earnings per share.

Several other research firms have also issued reports on COR. SVB Leerink restated an “outperform” rating and set a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th. Citigroup increased their target price on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Robert W. Baird raised their price target on Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.63.

Cencora Price Performance

COR stock opened at $239.82 on Monday. The firm has a market cap of $47.83 billion, a P/E ratio of 26.24, a P/E/G ratio of 1.68 and a beta of 0.45. The firm’s fifty day moving average is $229.77 and its 200 day moving average is $231.65. Cencora has a 52 week low of $171.65 and a 52 week high of $247.66. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.53 and a current ratio of 0.89.

Institutional Trading of Cencora

Hedge funds have recently modified their holdings of the business. Fisher Asset Management LLC bought a new position in Cencora during the 4th quarter valued at approximately $244,000. Trust Co. of Vermont bought a new position in shares of Cencora during the fourth quarter valued at $62,000. Wahed Invest LLC purchased a new position in shares of Cencora in the 4th quarter worth about $567,000. Vanguard Group Inc. bought a new position in Cencora in the 4th quarter worth about $4,212,508,000. Finally, Hennessy Advisors Inc. purchased a new stake in Cencora during the 4th quarter valued at about $3,307,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The disclosure for this sale can be found here. Insiders sold a total of 6,337,283 shares of company stock worth $1,476,300,791 over the last quarter. 15.80% of the stock is owned by corporate insiders.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Stockholders of record on Friday, August 9th will be paid a dividend of $0.51 per share. The ex-dividend date is Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.